Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Aneurysm

Clinical Trial Details

Overview

Research Study Summary

A clinical trial seeking patients for a research study for the treatment of Abdominal Aortic Aneurysms

Research Study Title

The Altura AAA Endograft Safety and Feasibility Study For Exclusion of Abdominal Aortic Aneurysms

Purpose

The purpose of this study is to evaluate the safety of deploying and implanting the Altura Abdominal Aortic Aneurysm (AAA) Endograft in the treatment of abdominal aortic aneurysms in subjects who are candidates for open surgical aneurysm repair.

To Learn more
Phase

1

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Altura Medical Inc.

Duration

34 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • 18 years or older.

  • Subject or subject's legal representative understands and has signed an informed consent.

  • Infrarenal aneurysmal neck diameter between 18 and 28mm, inclusive.

  • Abdominal aneurysm neck angulation < 45 degrees.

  • Infrarenal non-aneurysmal neck > /= 15mm in length.

  • Abdominal aneurysm > 4.5cm and growth > 1.0 cm/yr.

  • Limited iliac artery tortuosity.

  • Iliac artery fixation length of > /= 15mm.

  • Iliac artery diameter between 8 and 19 mm, inclusive.

  • Iliac artery diameter accessible by a 14 Fr introducer.

  • Subject is a candidate for open surgical repair of abdominal aortic aneurysm.

  • Patent iliac or femoral arteries access vessels, size and morphology to allow endovascular access of 14 Fr introducer sheaths and catheters.

  • Subject has > one year life expectancy.

  • Subject is not placed at additional risk while waiting for additional imaging necessary for vascular treatment.

  • Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive.

  • Subject is able and willing to comply with 30 day, six (6) month, one (1) year and 2 (two) year follow-up.

Exclusion Criteria:

  • Subject has an acutely ruptured or leaking or emergent aneurysm.

  • Subject has a dissecting aneurysm.

  • Subject has a mycotic or infected aneurysm.

  • Subject has current vascular injury due to trauma.

  • Subject's aneurysm is thoracic or suprarenal.

  • Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.

  • Subject has thrombus, calcification and/or plaque that may compromise sealing

  • Subject has had a myocardial infarction within six (6) months prior to enrollment.

  • Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease.

  • Subject has undergone other major surgery within the 30 days prior to enrollment.

  • Subject is pregnant or nursing.

  • Known allergy to nitinol or polyester or contrast material that cannot be pretreated.

  • Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.

  • Subject has connective tissue disease (e.g., Marfan's syndrome).

  • Subject has a bleeding disorder or anemia defined as hemoglobin < 9.0 mg/dL.

  • Subject is hypercoagulable.

  • Subject is on dialysis or has compromised renal function as reflected by a serum creatinine > 2.2 mg/dL.

  • Subject has compromised hepatic function as measured by SGPT (ALT) > three (3) times the upper limit of normal.

  • Subject has active systemic infection.

  • Subject is participating in another research study involving an investigational agent for the treatment of AAA.

  • Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.

Site Locations (2)

Country State City Zip Facility and Contact
Chile Santiago 8330024 Pontificia Universidad Catolica De Chile
Albrecht Kramer
kramer@med.puc.cl

Albrecht Kramer, MD
Principal Investigator
Latvia Riga LV-1002 Stradins University Hospital

Dainis Krievins, MD, PhD
Principal Investigator

Contact

Karina K Zarins
(650) 543-9223

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

NCT ID: NCT01346943

Date Last Changed: December 30, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.